PD-L1 Biomarker Testing market was valued at US$ 2088 million in 2022 and is anticipated to reach US$ 14870 million by 2029, witnessing a CAGR of 38.7% - Valuates Reports

PD-L1 Biomarker Testing market was valued at US$ 2088 million in 2022 and is anticipated to reach US$ 14870 million by 2029, witnessing a CAGR of 38.7% during the forecast period 2023-2029.

Get sample report - https://reports.valuates.com/request/sample/QYRE-Auto-6F9402/Global_PD_L1_Biomarker_Testing_Market_Size_Status_and_Forecast_2022

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti-PD-1/PD-L1 therapies.
PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2019 is about 21.68%.
PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2019 is about 52.7%.
North Americas is the largest consumption place, with a consumption market share nearly 55.63% in 2019. Following North Americas, Europe is the second largest consumption place with the consumption market share of 26.7%.

This report aims to provide a comprehensive presentation of the global market for PD-L1 Biomarker Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-L1 Biomarker Testing.
The PD-L1 Biomarker Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global PD-L1 Biomarker Testing market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PD-L1 Biomarker Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

Segment by Type
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Other

Segment by Application
Hospital
Diagnostic Center
Others

Get detailed report - https://reports.valuates.com/market-reports/QYRE-Auto-6F9402/global-pd-l1-biomarker-testing

Similar report -

https://reports.valuates.com/market-reports/QYRE-Auto-16X1161/global-st2-biomarker

https://reports.valuates.com/market-reports/QYRE-Auto-32R5863/global-oncology-biomarker

https://reports.valuates.com/market-reports/QYRE-Auto-5B8063/global-cancer-biomarker

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

Phone:
U.S. (TOLL FREE) : +1 (315) 215-3225
India: +91 8040957137

Email Id:
Please reach us at sales@valuates.com

This release was published on openPR.